Categories: World

Russia says its Sputnik V COVID-19 vaccine is 92% effective

Russia’s Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country’s sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

The initial results are only the second to be published from a late-stage human trial in the global race to produce a vaccine that could halt a pandemic that has killed more than 1.2 million people and ravaged the world economy.

Russia registered Sputnik V for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.

The interim results are based on data from the first 16,000 trial participants to receive both shots of the two-dose vaccine, the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, said.

The so-called Phase III trial of the shot developed by the Gamaleya Institute is taking place in 29 clinics across Moscow and will involve 40,000 volunteers in total, with a quarter receiving a placebo shot.

The chances of contracting COVID-19 were 92% lower among people vaccinated with Sputnik V than those who received the placebo, the RDIF said.

That’s well above the 50% effectiveness threshold for COVID-19 vaccines set by the U.S. Food and Drug Administration.

“We are showing, based on the data, that we have a very effective vaccine,” said RDIF head Kirill Dmitriev, adding that it was the sort of news that the vaccine’s developers would talk about one day with their grandchildren.

Russia’s announcement follows swiftly on from results posted on Monday by vaccine developers Pfizer Inc and BioNTech , who said their shot was also more than 90% effective.

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology and is designed to trigger an immune response without using pathogens, such as actual virus particles.

The Sputnik V vaccine is designed to trigger a response from two shots administered 21 days apart each based on different viral vectors that normally cause the common cold: human adenoviruses Ad5 and Ad26.

(Reuters)

 

R

Leave a Comment

Recent Posts

Mohamed Ali Fennira: industry committee denied renewal of exploitation of Ashtart and Rahmoura fields (Statement)

In a statement granted to Tunisie Numérique, MP and member of the Committee on Industry,…

2 heures ago

Rising temperatures: Forecast for next three days in all governorates

During the next three days, temperatures will surpass the average for June, exceeding normal by…

3 heures ago

NATO appoints Mark Rutte as next chief

The North Atlantic Treaty Organization (NATO) Council decided on Wednesday to name Mark Rutte, the current…

3 heures ago

Tunisia – Gafsa: Arrest of offender who attacked pharmacy

An offender known to the security authorities of the National Security district of Gafsa, born…

3 heures ago

Two ministers on working visit to Zaghouan

The Ministers of Tourism Mohamed Moez Belhassine and Youth Kamel Deguiche are making a working…

3 heures ago

Tunisian Embassy in Brussels reacts to Josep Borrell’s statements

The Embassy stressed that the Tunisian government legitimately represents the aspirations of the Tunisian people…

3 heures ago

This website uses cookies.